Organon Reports VTAMA Cream Achieves Early Skin Clearance in Children With Atopic Dermatitis
Organon & Co. announced results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream in children aged 2-17 with atopic dermatitis. The findings, which will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting on November 8, 2025, indicate that VTAMA cream provided early and consistent improvements in skin clearance, severity, patient-reported outcomes, and itch, regardless of the presence of atopic comorbidities such as asthma, allergic rhinitis, and food allergies. Clinically meaningful improvements in itch were observed as early as week 2, with continued improvement through week 8. The most frequently reported treatment-emergent adverse events included folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.